Cellectis (NASDAQ:CLLS) Share Price Crosses Below 50-Day Moving Average – What’s Next?

Shares of Cellectis S.A. (NASDAQ:CLLS) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $4.44 and traded as low as $4.36. Cellectis shares last traded at $4.41, with a volume of 32,000 shares.

Analysts Set New Price Targets

Several equities analysts have recently commented on CLLS shares. Wells Fargo & Company reiterated a “positive” rating and set a $4.00 target price on shares of Cellectis in a research note on Monday, October 20th. Clear Str raised shares of Cellectis to a “strong-buy” rating in a report on Tuesday, December 23rd. Wall Street Zen raised shares of Cellectis to a “hold” rating in a report on Saturday, September 20th. Barclays boosted their target price on shares of Cellectis from $4.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday, October 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Cellectis presently has an average rating of “Moderate Buy” and an average price target of $6.00.

Cellectis Stock Performance

The stock’s 50-day moving average price is $4.44 and its 200-day moving average price is $3.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.49 and a quick ratio of 1.49.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Friday, November 7th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.11. Cellectis had a negative net margin of 58.06% and a negative return on equity of 51.22%. The business had revenue of $37.16 million during the quarter, compared to the consensus estimate of $8.22 million. On average, research analysts expect that Cellectis S.A. will post -0.46 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Cellectis by 228.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after buying an additional 3,284,409 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Cellectis in the 3rd quarter worth about $633,000. Acadian Asset Management LLC increased its holdings in shares of Cellectis by 132.9% in the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 26,461 shares during the period. Virtu Financial LLC bought a new stake in Cellectis in the 3rd quarter valued at about $72,000. Finally, B Group Inc. boosted its stake in Cellectis by 0.8% during the 3rd quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock valued at $9,352,000 after purchasing an additional 25,000 shares during the period. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.